



1600

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/647,457A

DATE: 02/03/2003
TIME: 09:13:05

see p. 2

Input Set : A:\PTO.VSK.txt
Output Set: N:\CRF4\02032003\I647457A.raw

**Does Not Comply
Corrected Diskette Needed**

1 <110> APPLICANT: Yeda Research and Development
W--> 2 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW
W--> 3 <130> FILE REFERENCE: 1276302<140> 09/647,457<141> 2000-09-29<150>
C--> 4 <140> CURRENT APPLICATION NUMBER: US/09/647,457A
C--> 4 <141> CURRENT FILING DATE: 2003-01-24
4 <150> PRIOR APPLICATION NUMBER: 1999-09-29<150> 123925<151> 1998-04-02<160> 15 <170>

ERRORED SEQUENCES

E--> 25 <210> SEQ ID NO: 2<211> 28<212> PRT<213> Unknown<220><223> being the immunologically
W--> 26 active epitope
E--> 28 <211> LENGTH:
E--> 28 <212> TYPE:
E--> 28 <213> ORGANISM:
28 <400> SEQUENCE: 2
30 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
31 1 5 10 15
34 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
35 20 25
E--> 38 <210> SEQ ID NO: 3<211> 16<212> PRT<213> Unknown<220><223> peptide capable of binding
W--> 39 antibodies that are found in elevated
W--> 40 levels in body fluids of schizophrenic patients.
E--> 42 <211> LENGTH:
E--> 42 <212> TYPE:
E--> 42 <213> ORGANISM:
42 <400> SEQUENCE: 3
44 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
45 1 5 10 15
E--> 48 <210> SEQ ID NO: 4<211> 20<212> PRT<213> Unknown<220><223> peptide capable of binding
W--> 49 antibodies that are found in elevated
W--> 50 levels in body fluids of schizophrenic patients.
E--> 52 <211> LENGTH:
E--> 52 <212> TYPE:
E--> 52 <213> ORGANISM:
52 <400> SEQUENCE: 4
54 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
55 1 5 10 15
58 Ala Pro Cys Arg
59 20
E--> 62 <210> SEQ ID NO: 5<211> 19<212> PRT<213> Unknown<220><223> peptide capable of binding
W--> 63 antibodies that are found in elevated
W--> 64 levels in body fluids of schizophrenic patients

SEQUENCE LISTING<110> Yeda Research and Development
Company Ltd.<120> ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW
PEPTIDE<130> 1276302<140> 09/647,457<141> 2000-09-29<150>
PCT/IL99/00190<151> 1999-09-29<150> 123925<151> 1998-04-02<160> 15 <170>
PatentIn version 3.1<210> 1<211> 17<212> PRT<213> Unknown<220><223> an
isolated peptide which binds antibodies.

<220><221> MISC_FEATURE<222> (1)..(17)<223> Xaa in position 1 is selected
from the group consisting of SGATED. *FBI: Xaa can only represent a single amino acid,
nothing
else*
TFIAD, IAD, AD, D and a direct bond; Xaa in position 9 is selected
from the group consisting of C, G, and P; Xaa in position 15 is s
elected from the group consisting of AP, and PA; Xaa in position
17 is R, or a direct bond, group.

<400> 1 see above for explanation of Xaa

Xaa Leu Val Val Gly Leu Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Cys
1 5 10 15


Xaa

(sample of submitted file)


major format errors

Please contact Robert Wax at 703-306-4119 or
703-308-4216

for assistance



BIOTECHNOLOGY
SYSTEMS
BRANCH



**RAW SEQUENCE LISTING
ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/647,457A
Source: 1600
Date Processed by STIC: 2/3/2003

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER
VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>


Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual- ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or,
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



#194
Dmt
4-21-03

BOX SEQUENCE
Attorney Docket No. 24390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SHINITZKY et al.

Examiner: S. Turner

Serial No.: 09/647,457

Art Unit: 1647

Filed: November 29, 2000

For: **ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON
A NEW PEPTIDE**

SEQUENCE LISTING SUBMISSION STATEMENT

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
APR 17 2003
TECH CENTER 1600/2900

Sir:

This is in response to the Notice to Comply with Sequence Requirements mailed March 26, 2003, with a one-month period for response. A substitute Sequence Listing is due to be filed April 26, 2003. Accordingly, this new Sequence Listing is timely filed within the period set for reply by the Examiner.

In connection with the Sequence Listing submitted herewith, the undersigned attorney hereby states that:


- 1) The submission, filed herewith in accordance with 37 CFR 1.821(g), does not include new matter; and
- 2) The content of the attached paper copy and the attached computer readable copy of the Sequence Listing are the same.

Date: April 15, 2003

Respectfully submitted,
NATH & ASSOCIATES PLLC

NATH & ASSOCIATES PLLC
1030 15th Street NW, 6th Floor
Washington, D.C. 20005
Tel: (202) 775-8383
Fax: (202) 775-8396

GMN:TLJ/SMM\seq.state


Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529